Balanced news tone
News Sentiment
BEAM sentiment intelligence
Beam Therapeutics Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
53
Balanced news tone
13 relevant articles
Price is moving more forcefully than the current news tone suggests.
90/100 classification confidence.
directly relevant articles
high-authority source matches
+4.2% over one week, +23.9% over four weeks, trend active, and near fair-value range.
Beam Therapeutics stock soars 21% in three months: Here's why
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
90/100 classification
One-week reaction
4.2%
Price confirming higher
Trend fit
Trend active
23.9% over four weeks
Fair value
10.7%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
4
Neutral
9
Negative
0
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
MSN
Direct company coverage
Beam Therapeutics stock soars 21% in three months: Here's why
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 21:07
- Source
- MSN
Stock Titan
Direct company coverage
Beam Therapeutics president exercises 35,505 options | BEAM Insider Trading
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 20:05
- Source
- Stock Titan
Investing.com
Direct company coverage
Beam Therapeutics stock hits 52-week high at 36.66 USD
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 13:55
- Source
- Investing.com
simplywall.st
Direct company coverage
Why Beam Therapeutics (BEAM) Is Up 16.1% After FDA Clears Platform-Based PKU Gene-Editing Trial
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 18:56
- Source
- simplywall.st
ChartMill
Direct company coverage
BEAM News | BEAM THERAPEUTICS INC (NASDAQ:BEAM)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 00:00
- Source
- ChartMill
Market source
Direct company coverage
Is Beam Therapeutics Inc. (BEAM) One of the Best Genomics Stocks to Buy According to Analysts?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 16 Jun 2026 12:53
- Source
- Market source
The Motley Fool
Direct company coverage
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 May 2026 07:00
- Source
- The Motley Fool
Market source
Direct company coverage
Two Programs That Could Make or Break Beam Therapeutics Inc (BEAM) Stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 May 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Beats Revenue Estimates
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 07 May 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Is Beam Therapeutics Inc. (BEAM) A Good Stock To Buy Now?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 02 May 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Jim Cramer Believes Beam Therapeutics Is a “Speculative Situation”
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Apr 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 12 Mar 2026 07:00
- Source
- Market source
StockInvest.us
Direct company coverage
Beam Therapeutics Stock Price Forecast. Should You Buy BEAM?
- Tone
- Positive 66/100
- Event
- Guidance
- Published
- 01 Dec 2020 20:47
- Source
- StockInvest.us